Though the term apoptosis was originated in pathology and developmental biology as an alternative to necrosis, the tissue necrosis with inflammation is irrelevant to cell culture conditions where apoptosis is mostly studied. Furthermore, no one single morphological feature is either necessary or sufficient to define apoptosis. The emerging biochemical definition, a cell death with caspase activation, allows the distinction of alternative forms of cell death. Thus, inhibition of caspases delays but does not prevent cell death. Slow cell death without caspase activation may nevertheless be associated with DNA fragmentation. Oncogenic Ras, Raf, and mitogen-activated kinases inhibit apoptosis by affecting the cytochrome C/caspase-9 pathway but may arrest growth and cause slow cell death with delayed DNA fragmentation. Such 'slow' cell death without caspase activation is often caused by chemotherapeutic drugs. Whether a cell will undergo apoptosis or slow death depends not only on a chemotherapeutic agent but also on the readiness of cellular caspases. Therefore, one can distinguish apoptosisprone (eg leukemia) vs apoptosis-resistant cells. Cell susceptibilities to spontaneous, starvation-induced and drug-induced apoptosis are correlated and characterize an apoptosis-prone phenotype. Finally, distinction of slow cell death allows rephrasing of a question regarding the goal of cancer therapy: apoptosis vs slow cell death, or cancer cell-selectivity regardless of the mode of cell death. Leukemia (2000) 14, 1502-1508.
Introduction
Until recently, deciding whether cell death in cell culture occurs through apoptosis or non-apoptosis (ie necrosis) has been reminiscent of the medieval debate regarding the number of angels that can fit on the head of a pin. Despite the description of apoptosis in vivo, 1 a lack of a strict definition for apoptosis coupled with underfined alternatives to apoptosis often lead to controversy. As noted by Vaux, 2 the absence of precise meaning for the terms used can lead to several mutually exclusive, but correct answers. Apoptosis has been commonly described but not defined from four different points of view: (1) 'Programmed' cell death (PCD), even though 'program' originally referred to the development of an organism. 3 While, in developmental biology, PCD occurs through apoptosis, in cancer and cell biology, it has, ironically, been rephrased that apoptosis occurs through PCD. (2) Cell death which is non-necrotic, even though the term tissue necrosis is not applicable to cell culture, where apoptosis is mostly studied. The term apoptosis was originally used to distinguish a type of cell death without inflammatory tissue injury from necrotic cell death in multicellular organism. 1 In vivo, due to a release of cytoplasmic constituents to intercellular space, necrosis triggers the inflammatory response in tissue often resulting in scar formation. In contrast, the remains of apoptotic cells are phagocytized by surrounding cells. The distinction of tissue necrosis from cell apoptosis is arbitrary because of the irrelevance of the pathological term 'tissue necrosis' to the cell culture. As a consequence, every type of cell death which did not fulfill arbitrary criteria of apoptosis were called necrosis. Moreover, 'necrosis' is used to refer to very different forms of cell death. At one extreme there is an ultrarapid cell death. At the other end of the spectrum there is slow cell death: eg cell senescence was described as necrosis-like death or delayed necrosis. 4 (3) A combination of morphological features (nuclear fragmentation, DNA degradation, cell shrinkage, membrane bledding, chromatin condensation), even though each of them are neither essential nor sufficient. This results in such terms as necrosis with apoptotic morphology or apoptosis with necrotic morphology. 4 (4) An active process of dying that requires energy and de novo gene expression, even though inhibitors of transcription/translation often induce apoptosis or, at least, do not inhibit apoptosis. [5] [6] [7] [8] [9] A dead cell is characterized by irreversible cessation of metabolism and inability to exclude substrates, for example, the inability to metabolize MTT and to exclude trypan blue. Apoptosis (as well as other forms of cell death) is a process of dying and until the cell is dead, it may exclude trypan blue or exhibit any other markers of a living cell. 10 Therefore, using the common characteristics of a dead cell, one cannot distinguish apoptosis and other forms of cell death (eg necrosis).
Emerging definition for apoptosis: caspase-mediated cell death
A canonical example of apoptosis is a rapid death of Jurkat cells following exposure to FasL. The process is initiated on cellular membranes by recruiting caspase-8 to the cytosolic domain of ligated Fas. 11, 12 Caspases are cysteine proteases which cleave intracellular proteins including downstream caspases. [13] [14] [15] Since the Fas-induced cell death requires presynthesized caspases, receptor to FasL and adaptor proteins, the process is genetically programmed but does not depend on protein synthesis. Most other apoptotic stimuli (including chemotherapeutic drugs) activate the 'mitochondrial' pathway which involves the activation of caspase-9 by mitochondrial products leading to caspase-3 activation. 16 Caspase activation brings about DNA fragmentation and laddering due to the caspase-mediated activation of nucleases which cleave DNA into internucleosomal fragments. [17] [18] [19] [20] [21] Also, cleavage of cytoskeletal proteins contributes to membrane bledding, nuclear breakdown, cell shrinkage and other morphological features 22 and appearance of phosphatidylserine (PS) on the cell surface. 23 Externalization of phosphatidylserine signals phagocytosis, and therefore caspase activation prevents tissue necrosis in vivo. Irreversible cleavage of key proteins ensures inevitable cessation of synthesis and metabolism: a cell death.
A definition of apoptosis is emerging as cell death associa-although, as noticed by Vaux, the definition may be weakened by referring to apoptotic morphology. 2 Simply, 'apoptotic morphology' should not appear in the definition. Cell death with caspase activation is sufficient and necessary for apoptosis whereas specific morphological changes can be considered as mere markers of caspase activation if they can be abolished by the inhibitors of caspases. This definition provides easily measurable markers such as PARP cleavage or externalization of phosphatidylserine. In contrast, as shown in Figure 1 , DNA internucleosomal fragmentation may or may not be a consequence of caspase activation. [25] [26] [27] [28] [29] DNA degradation is not required for apoptotic cell death, 30 and, on the other hand, caspases are not required for endonuclease activation in the cell-free system. 31 By definition, caspase activation without death 32 is not apoptosis. In addition, the term 'apoptosis without caspase activation' contradicts the definition.
Alternative forms of cell death: apoptosis vs slow cell death
Inhibition of caspases often blocks cell shrinkage, externalization of phosphatidylserine, nuclear condensation, or DNA fragmentation, but the cells still eventually die. 33, 34 For example, zVAD-fmk, an inhibitor of the caspases, interferes with all the morphological and biochemical changes associated with apoptosis induced by DNA damaging drugs. Nonetheless, the insulted cells eventually die with cytoplasmic and nuclear vacuolization. 34 In other cases, 'apoptotic' morphologies (shrinkage, membrane bledding and nuclear condensation) are not blocked by caspase inhibitors but the cells continue to die in a protractive and inefficient manner. 35 Thus, inhibitors of caspases block apoptosis but cells may die of delayed 'necrosis', which I will refer to as slow cell death ( Figure 1 ).
Slow cell death occurs if caspases are inhibited or absent. As the most obvious case, some cell lines are deficient in caspases, for example caspase-3, 19, 36 and therefore die by slow cell death. Non-apoptotic cell death without caspase activation may occur despite cytochrome C release. 10 Even
Figure 1
Relationship between DNA fragmentation, apoptosis, and slow cell death. DNA fragmentation can occur during either apoptosis (cell death with caspase activation) or slow cell death without caspase activation.
Leukemia more important, slow cell death is a rule rather than an exception in fibroblast and most cancer cells, although it may be labelled as drug resistance. 37 Furthermore, it has been shown that loss of interdigital cells in an embryo, a paradigm of cell death during development, may be non-apoptotic. 30 Therefore, slow cell death is an alternative mode of cell death. What about necrosis? Is necrosis relevant to cell culture? As emphasized by Samali et al, 24 there is a shift from apoptosis to necrosis with increasing concentration of a toxic compound. Often necrosis develops as ultra-fast cell death following particularly strong stimuli (Figure 2) . Perhaps the term necrosis should be reserved for tissue necrosis in the animal or human organism and, at the very least, to ultra-fast cell death which develops before any caspase activation could occur (Figure 2 ).
Inhibition of apoptosis with induction of slow cell death
Regulators of apoptosis are not purely pro-apoptotic or antiapoptotic. In the Bcl-2 family, Bcl-2 and BclxL are anti-apoptotic protein whereas Bax and BAD are pro-apoptotic. 38 However, Bcl-2 may be apoptotic when grossly overexpressed, 39 or converted from anti-apoptotic to apoptotic by Bcl-2 protein cleavage, 40 which may accompany chemotherapy. 41, 42 In contrast, the low levels of p53 that otherwise is almost a symbol of apoptosis protect against apoptosis in some cell models. 43 As is well known, oncogenes that stimulate proliferation can induce apoptosis. 44 These pro-apoptotic oncogenes such as c-myc, E2F, cyclin D1, E1A activate downstream segments of growth stimulatory pathways. In contrast, 'upstream' oncogenes block apoptosis but may inhibit cell growth. 45 The growth factor-dependent kinases (PI3-kinase, Raf kinases, MEK/MAPK) suppress apoptosis downstream of the release of cytochrome C from mitochondria. 46, 47 Phosphorylation of BAD is a common mechanism of anti-apoptotic activity. 48 Bcr-Abl, a kinase activated in chronic myeloid leukemia, prevents the cytochrome C release thus delaying cell death in the Bcr-Abl positive K562 leukemia cells. 49, 50 Thus, anti-apoptotic oncogenes and kinases can prevent cytochrome C release and caspase-9 activation 46,47,51 ( Figure 3 ). Remarkably, even these anti-apoptotic oncogenes may induce cell death. 52 As an intriguing example, Ras plays a dual role in the cell death, 53 that can be reconciled if one recognizes slow cell death as the alternative to apoptosis. Antiapoptotic oncogenes can induce slow cell death. For example, in intestinal epithelial cells, apoptosis is suppressed by c-H-ras oncogene. 54 Ras suppresses apoptosis by activating Raf-1/MAPK, P13 and other kinases 46 ( Figure 3 ). On the other hand, Ras may signal growth arrest due to induction of CDK inhibitors (see Ref. 45) . Growth arrest can be associated with cell senescence. 55 This eventually results in slow cell death (Figure 3 ). In fact, Ras induces cellular degeneration
Figure 2
Approximate time frame for 'necrosis', apoptosis, and slow cell death.
Figure 3
Inhibition of apoptosis but induction of slow cell death by Ras/Raf/MEK. accompanied by cytoplasmic vacuoles, well-preserved nuclei in the absence of caspase activation, 56 and protease inhibitors only marginally affected Ras-mediated cell death. 57 Ras causes formation of giant multinucleated cells culminating in 'mitotic' death, 58 the term which may be synonymous with slow cell death. Giant multinucleated cells were also observed in p21-associated slow cell death caused by proteasome inhibitors in MCF-7, an apoptosis-resistant cell line. 59 Like Ras, Raf-1 suppresses apoptosis, 60, 61 but can induce slow cell death with DNA fragmentation in caspase-3-deficient MCF-7 cancer cells. 62 In addition, phorbol ester (PMA), an activator of PKC/MAPK pathway, plays the dual role in cell death. In human Rasexpressing epithelial cells, PMA causes microscopic features of death (chromatin condensation, TdT labelling) and DNA fragmentation after a surprising lag of 4 days. 63 This can be explained if it is considered that DNA fragmentation may be a sign of slow cell death, as well as that of apoptosis. While PMA did not cause caspase activation in HL60 cells, 42 it causes DNA fragmentation and delayed slow cell death. 64 Furthermore, PMA-induced differentiation blocks DNA fragmentation associated with apoptosis. 6 Slow cell death is associated with PMA-induced growth arrest in SKBr3 breast cancer cells, whereas induction of proliferation in PMA-arrested cells by E1A converts death from slow to apoptotic. 65 On the other hand, PMA prevents apoptosis caused by IL-3 withdrawal. 66 Thus, Ras and MAPK inhibit apoptosis by affecting the cytochrome C/caspase-9 pathway but in some circumstances, may signal growth arrest due to the induction of CDK inhibitors (Figure 2 ). This growth arrest may lead to slow cell death, often called apoptosis on the basis of the delayed DNA fragmentation.
Proapoptotic drug-or apoptosis-prone cells
Like physiological stimuli and oncogenes, chemotherapy can induce either apoptosis or slow cell death which is also called the senescence-like phenotype. 67 Although a drug concentration may determine the response, 68, 69 the choice between apoptosis and slow death significantly depends on a cell. Too easily, the ability of a chemotherapeutic agent to cause apoptosis in lymphoid or leukemic cells labels such drug as 'apoptotic', even though it does not necessarily induce apoptosis in other cells. As much as a drug may be potentially apoptotic, the cell may be apoptosis-prone. In brief, drugs induce apoptosis in apoptosis-prone cells.
Apoptosis-resistant phenotype is illustrated by the crossresistance to different cytotoxic regimens in tumor cells because of failure of caspase-activation. 70, 71 A constitutive readiness of caspases confers the apoptosis-prone phenotype, whereas the downmodulation of caspase activities can enhance chemoresistance. 72 It would be virtually impossible to find a cytotoxic agent that would not induce apoptosis in Jurkat leukemia cells and, to a lesser degree, HL-60 and U937 cells. 9, [73] [74] [75] In comparison with Jurkat and HL-60 cells, K562 CML cells are relatively resistant to apoptosis induced by a variety of stimuli, because the activation of caspase-3 is delayed or absent in K562 cells. 49, 50, [76] [77] [78] [79] Spontaneous apoptosis in leukemic cells in vitro correlated with drug sensitivity. [80] [81] [82] Although leukemia cells are sensitive to apoptosis induced by serum starvation, epithelial cancer cells do not require serum for survival. 81 Also, drug-resistant leukemic cells are resistant to serum starvation and differentiationinducing agents. 83 Thus, spontaneous apoptosis, growth factor starvation-induced apoptosis and drug-induced apoptosis are correlated characterizing the apoptosis-prone phenotype. Cowpox virus CrmA protein, a direct and specific inhibitor of caspase proteases prevented apoptosis in a leukemia cell line leading to delayed death and even cell recovery and repopulation. 72 Furthermore, MCF-7 breast cancer cells lacking caspase-3 are resistant to apoptosis by numerous stimuli, 25 ,84 but undergo growth arrest followed by slow cell death. 78 Like MCF-7 cells, many other epithelial cancer cells die without caspase activation. 10 Sensitivity to drug-induced cell death depends on intact apoptotic pathways leading to activation of caspases. 85 Defects in the activation of the caspase-3 proteolytic system upon treatment with chemotherapeutic compounds is associated with resistance to apoptosis. 86 Perhaps in epithelial cancer cell lines the frequency of apoptosis is overestimated. Usually DNA fragmentation or chromosome condensation is arbitrarily used to claim apoptosis in many studies, including my own. In contrast, caspase activation is rarely reported in cancer cells. However, DNA fragmentation could be caspase-independent. 28, 87 In addition, AIF causes chromatin condensation and large scale DNA fragmentation to fragments of approximately 50 kbp (see Ref. 88) . Especially, high molecular weight DNA fragmentation is not specific to apoptosis. 89 Furthermore, drugs or serum starvation can induce apoptosis without concomitant internucleosomal degradation of DNA. 25, 26, 90 Such features as chromosome condensation are especially troublesome in apoptosis caused by microtubule-active drugs which cause chromosome condensation as a part of mitotic arrest. Even in leukemia, the cells with DNA breaks were identified in blood for up to 5 days following chemotherapy, 91 that, in my opinion, is consistent with slow cell death.
A drug can induce apoptosis in some but not every cancer cell line, and I will provide examples of traditional and experi-mental therapeutics in order of increasing apoptotic potential. Glucocorticoids induce apoptosis in CLL (see Ref. 92) , while they are not toxic to most non-lymphoid cells. In leukemia cell lines, microtubule-active drugs such as paclitaxel induce caspase activation culminating in cell death in 16-36 h, 42, 93 but many cancer cell lines undergo slow cell death for 3-6 days. Like microtubule active, DNA damaging drugs induce apoptosis in leukemia cells. 41, 94 DNA damaging drugs may induce slow cell death in cancer cells and fibroblasts. 84, 95 Experimental therapeutics, such as flavopiridol and UCN-01, induce apoptosis in leukemia cells, 96, 98 whereas some cancer cell lines including PC3 prostate cancer cell line are resistant. 84, [99] [100] [101] Nevertheless, flavopiridol induces DNA fragmentation in squamous cell carcinomas resistant to DNAdamaging drugs. 102 Inhibitors of the proteasome induce apoptosis [103] [104] [105] even in PC-3 cell line. 106 Growth arrest without apoptosis was observed in caspase-3-deficient MCF-7 cells 78 and such apoptosis-resistant cells as normal fibroblasts.
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Conclusions
With necrosis as an alternative to apoptosis, the statement 'apoptosis is a goal of cancer therapy' seems controversial. While apoptosis is utilized in the program of development of an organism to avoid the scar associated with necrosis, there is no goal to avoid tumor necrosis in cancer therapy. Chemotherapy may fail not because it causes tumor necrosis, but because it does not cause cell death. Despite the assumption that apoptosis is a response to DNA damage in order to prevent tumorigenesis, there is no evidence that apoptosis evolved by nature to fight against cancer. It is rather utilized in the development of an organism and in control of selfrenewing tissues: leukocytes, lymphocytes, epithelium. 108, 109 Although the suppression in apoptosis contributes to carcinogenesis, 44, 110, 111 self-renewing tissues are the main source of neoplasms. Therefore, apoptosis (as a goal of therapy) is an alternative to cancer cell survival. [112] [113] [114] The discrimination of slow cell death from apoptosis allows rephrasing of the key question: is the goal of cancer therapy apoptosis or slow cell death. Although significance of apoptosis compared with replicative or slow death in cancer chemotherapy was not widely discussed, there are indications that apoptosis may be a desirable goal. There are better results in chemotherapy of apoptosis-prone tumors, 95, 111 and the lack of apoptosis correlated with failure to achieve complete remission. 115 Leukemia cells readily undergo apoptosis, and leukemias are more susceptible to chemotherapy than most solid cancers. 95, [116] [117] [118] Even if a cell cannot undergo apoptosis, it can still die by slow death. Perhaps selectivity in killing cancer cells without killing normal cells is as important a goal of cancer therapy as is the mode of death taken by the cancer cell. Pardee and James 119 demonstrated a selective protection of normal cells, utilizing a restriction point by normal but not cancer cells. 120 Recent advances in oncogenes and signal transduction studies allow the exploitation of more detailed differences to protect normal cells. Thus, pharmacological inactivation of wt p53 may protect cells from the cytotoxic doses of DNA damaging drugs, 121 whereas induction of wt p53 by low cytostatic doses allows the protection of these cells but not p53-deficient cancer cells from paclitaxel and vinblastine. 122 Furthermore, a selective protection of normal cells may be achieved exploiting an adverse feature such as multidrug resistance, which is otherwise an obstacle for treatment.
